Isamu Tsuji is currently serving as a Senior Scientist at the Vaccine Bioassay Development group in Takeda Pharmaceutical Inc. He obtained his Ph.D. in Biology from the University of Tsukuba in 2024. With professional experience that includes principal and senior scientist positions at Takeda, Isamu Tsuji has developed expertise in antibody discovery, assay development, protein purification, and cell-based assays. His research interests currently focus on generating and characterizing monoclonal antibodies for viral diseases such as Zika, Dengue, and COVID-19, as well as developing innovative immunoassays for vaccine evaluation. Previous work has included cancer antibody discovery and the advancement of high-throughput mAb screening techniques. He has published 17 papers and is an inventor on 7 patents related to antibody assays and protein production, and is active in presenting at international scientific meetings